enfortumab vedotin
astellas,seagen
['ev-301']
dr. matthew milowsky discusses the update results of ev-301 trial with 24mth mfu. very similar numbers as the nejm publication with a plateau pfs around 15-20%. #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer